2024 ASTRO Coding and Coverage Seminar -SRS and SBRT

Topics Included:

2024 ASTRO Coding and Coverage Seminar - Brachytherapy and Radiopharmaceuticals

Topics Included:

1. Brachytherapy
Participants will learn about the radiation therapy modality of brachytherapy. Codes specific to this modality are addressed. ASTRO’s Brachytherapy Model Policy is reviewed in detail.

2024 ASTRO Coding and Coverage Seminar - Protons, 3-D and IMRT

Topics Included:

1. Proton Beam Therapy
Participants will learn about the proton beam therapy (PBT) radiation modality and codes. ASTRO’s Proton Beam Therapy Model Policy is reviewed in detail. 

2024 ASTRO Coding and Coverage Seminar - Radiation Oncology Coding Landscape and Prior Authorization

Topics Included:

Navigating Medical Insurance Delays and Denials: Insights from Patients, ASTRO and the Press

Navigating medical insurance for radiation treatment in the United States is frustrating and complex, often resulting in disappointment for patients, delays in care, and denials of standard of care treatment.

Practical Elements of a Radiopharmaceutical Program: Findings from ASTRO's Safety White Paper

Despite the rapid advancements, there exists a gap in the integration of radiopharmaceutical therapy within radiation oncology practices.

Is Consolidation Radiotherapy Still Needed for Lymphoma in 2024? Reappraisal in Light of Recent Trials Results

Radiotherapy plays an important role as a consolidation treatment after systemic therapy, either to shorten the course of systemic therapy and reduce hematological, cardiac and fertility toxicity or to reduce the risk of relapse e.g., for bulky masses.

At the Cutting Edge: The Increasing Role of Salvage Radiotherapy in Relapsed/Refractory Lymphomas

Recently, there have been exciting advances in the treatment of relapsed/refractory (R/R) lymphomas. Historically, the standard-of-care included salvage chemotherapy followed by autologous stem cell transplantation (ASCT). Today, many other salvage options are available.

Beyond Counting on Our Fingers: The Current State and Future Management of Oligometastatic Lung Cancer

There is a high degree of variability in the management and even the understanding of the oligometastatic state in lung malignancies, or indeed in the context of any solid tumor.

Hypofractionation for Soft Tissue Sarcoma

Modern trends throughout radiation oncology have favored short-course hypofractionated regimens which are frequently more cost-effective and convenient for patients. Over the past two years, multiple prospective studies have emerged supporting hypofractionation in soft tissue sarcoma.

Pages

Subscribe to RSS - Sessions onDemand